Access the full text.
Sign up today, get DeepDyve free for 14 days.
I. Rauscher, T. Maurer, A. Beer, F. Graner, B. Haller, G. Weirich, A. Doherty, J. Gschwend, M. Schwaiger, M. Eiber (2016)
Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage LymphadenectomyThe Journal of Nuclear Medicine, 57
R. Stoyanova, M. Takhar, Y. Tschudi, J. Ford, G. Solórzano, N. Erho, Y. Balagurunathan, S. Punnen, E. Davicioni, R. Gillies, A. Pollack (2016)
Prostate cancer radiomics and the promise of radiogenomics.Translational cancer research, 5 4
C. Uprimny, A. Kroiss, C. Decristoforo, J. Fritz, B. Warwitz, L. Scarpa, Llanos Roig, D. Kendler, E. Guggenberg, J. Bektic, W. Horninger, I. Virgolini (2017)
Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 44
M. Eiber, G. Weirich, K. Holzapfel, M. Souvatzoglou, B. Haller, I. Rauscher, A. Beer, H. Wester, J. Gschwend, M. Schwaiger, T. Maurer (2016)
Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.European urology, 70 5
A Fedorov, MG Vangel, CM Tempany, FM Fennessy (2017)
Multiparametric Magnetic Resonance Imaging of the Prostate: Repeatability of Volume and Apparent Diffusion Coefficient QuantificationInvest Radiol, 52
W. Fendler, Dorothea Schmidt, V. Wenter, K. Thierfelder, C. Zach, C. Stief, P. Bartenstein, T. Kirchner, F. Gildehaus, C. Gratzke, C. Faber (2016)
68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate CancerThe Journal of Nuclear Medicine, 57
P. Gibbs, G. Liney, M. Pickles, B. Zelhof, G. Rodrigues, L. Turnbull (2009)
Correlation of ADC and T2 Measurements With Cell Density in Prostate Cancer at 3.0 TeslaInvestigative Radiology, 44
S. Borofsky, A. George, S. Gaur, M. Bernardo, M. Greer, Francesca Mertan, M. Taffel, Vanesa Moreno, M. Merino, B. Wood, P. Pinto, P. Choyke, B. Turkbey (2018)
What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.Radiology, 286 1
L. Domachevsky, H. Bernstine, N. Goldberg, M. Nidam, D. Stern, J. Sosna, D. Groshar (2017)
Early 68GA-PSMA PET/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET/CT.Clinical radiology, 72 11
S. Isebaert, L. Bergh, K. Haustermans, S. Joniau, E. Lerut, L. Wever, F. Keyzer, T. Budiharto, P. Slagmolen, H. Poppel, R. Oyen (2013)
Multiparametric MRI for prostate cancer localization in correlation to whole‐mount histopathologyJournal of Magnetic Resonance Imaging, 37
Nadine Woythal, R. Arsenić, C. Kempkensteffen, K. Miller, J. Janssen, K. Huang, M. Makowski, W. Brenner, V. Prasad (2017)
Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate CancerThe Journal of Nuclear Medicine, 59
Andrey Fedorov, M. Vangel, C. Tempany, F. Fennessy (2017)
Multiparametric Magnetic Resonance Imaging of the ProstateInvestigative Radiology, 52
(2011)
Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging
Jing Wang, Chen‐Jiang Wu, Mei‐Ling Bao, Jing Zhang, Xiao-ning Wang, Yu-Dong Zhang (2017)
Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancerEuropean Radiology, 27
See Kim, M. Choi, M. Kim, Young Kim, S. Cho (2017)
Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis.AJR. American journal of roentgenology, 209 4
G. Metzger, C. Kalavagunta, B. Spilseth, P. Bolan, Xiufeng Li, D. Hutter, J. Nam, Andrew Johnson, Jonathan Henriksen, L. Moench, B. Konety, C. Warlick, S. Schmechel, J. Koopmeiners (2016)
Detection of Prostate Cancer: Quantitative Multiparametric MR Imaging Models Developed Using Registered Correlative Histopathology.Radiology, 279 3
S. Koerber, Maximilian Utzinger, C. Kratochwil, C. Kesch, M. Haefner, S. Katayama, W. Mier, A. Iagaru, K. Herfarth, U. Haberkorn, J. Debus, F. Giesel (2017)
68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical ParametersThe Journal of Nuclear Medicine, 58
Sarah Schwarzenboeck, I. Rauscher, C. Bluemel, W. Fendler, S. Rowe, M. Pomper, Ali Asfhar-Oromieh, K. Herrmann, M. Eiber (2017)
PSMA Ligands for PET Imaging of Prostate CancerThe Journal of Nuclear Medicine, 58
J. Barentsz, J. Weinreb, S. Verma, H. Thoeny, C. Tempany, F. Shtern, A. Padhani, D. Margolis, K. Macura, M. Haider, F. Cornud, P. Choyke (2016)
Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use.European urology, 69 1
T. Maurer, J. Gschwend, I. Rauscher, M. Souvatzoglou, B. Haller, G. Weirich, H. Wester, M. Heck, H. Kübler, A. Beer, M. Schwaiger, M. Eiber (2016)
Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.The Journal of urology, 195 5
B. Turkbey, P. Choyke (2015)
PIRADS 2.0: what is new?Diagnostic and interventional radiology, 21 5
Kirsten Carlaw, H. Woo (2017)
Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016Prostate International, 5
P. Pepe, D. D'Urso, A. Garufi, G. Priolo, M. Pennisi, G. Russo, M. Sabini, L. Valastro, A. Galia, F. Fraggetta (2017)
Multiparametric MRI Apparent Diffusion Coefficient (ADC) Accuracy in Diagnosing Clinically Significant Prostate Cancer.In vivo, 31 3
Moritz Kasel-Seibert, T. Lehmann, René Aschenbach, F. Guettler, M. Abubrig, M. Grimm, U. Teichgraeber, T. Franiel (2016)
Assessment of PI-RADS v2 for the Detection of Prostate Cancer.European journal of radiology, 85 4
T. Pyka, Shozo Okamoto, Marielena Dahlbender, R. Tauber, M. Retz, M. Heck, N. Tamaki, M. Schwaiger, T. Maurer, M. Eiber (2016)
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 43
Sam Chang (2004)
Overview of prostate-specific membrane antigen.Reviews in urology, 6 Suppl 10
R. Gillies, Paul Kinahan, H. Hricak (2015)
Radiomics: Images Are More than Pictures, They Are DataRadiology, 278
Lindsey Torre, R. Siegel, E. Ward, A. Jemal (2015)
Global Cancer Incidence and Mortality Rates and Trends—An UpdateCancer Epidemiology, Biomarkers & Prevention, 25
M. Yoon, Juhyun Park, J. Cho, C. Jeong, J. Ku, Hyeon-Hoe Kim, C. Kwak (2017)
Predicting biochemical recurrence in patients with high-risk prostate cancer using the apparent diffusion coefficient of magnetic resonance imagingInvestigative and Clinical Urology, 58
A. Kido, T. Tamada, T. Sone, N. Kanomata, Y. Miyaji, A. Yamamoto, Katsuyoshi Ito (2017)
Incremental value of high b value diffusion-weighted magnetic resonance imaging at 3-T for prediction of extracapsular extension in patients with prostate cancer: preliminary experienceLa radiologia medica, 122
T. Hambrock, D. Somford, H. Huisman, I. Oort, J. Witjes, C. Kaa, T. Scheenen, J. Barentsz (2011)
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer.Radiology, 259 2
David Silver, Inmaculada Pellicer, W. Fair, W. Heston, C. Cordon-Cardo (1997)
Prostate-specific membrane antigen expression in normal and malignant human tissues.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 1
Objectives To quantitatively characterize clinically significant intra-prostatic cancer (IPC) by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11 positron emission tomography/magnetic resonance (PET/MR). Methods Retrospective study approved by the institutional review board with informed written consent obtained. Patients with a solitary, biopsy-proven prostate cancer, Gleason score (GS) ≥7, presenting for initial evaluation by PET/computerised tomography (PET/CT), underwent early prostate PET/MR immediately after PSMA-11 tracer injec- tion. PET/MR [MRI-based attenuation correction (MRAC)] and PET/CT [CT-based AC (CTAC)] maximal standardised uptake value (SUVmax) and minimal and mean apparent diffusion coefficient (ADCmin, ADCmean; respectively) in normal prostatic tissue (NPT) were compared to IPC area. The relationship between SUVmax, ADCmin and ADCmean measurements was obtained. Results Twenty-two patients (mean age 69.5±5.0 years) were included in the analysis. Forty-four prostate areas were evaluated (22 IPC and 22 NPT). Median MRAC SUVmax of NPT was significantly lower than median MRAC SUVmax of IPC (p < 0.0001). Median ADCmin and ADCmean of NPT was significantly higher than median ADCmin and ADCmean of IPC (p < 0.0001). A very good correlation was found between MRAC SUVmax with CTAC SUVmax (rho = –0.843, p < 0.0001). A good inverse relationship was found between MRAC SUVmax and
European Radiology – Springer Journals
Published: May 30, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.